[The stabilization of physostigmine preparations]. 1987

G Raether, and M Pranz, and H Wollmann

UI MeSH Term Description Entries
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs

Related Publications

G Raether, and M Pranz, and H Wollmann
February 1985, Die Pharmazie,
G Raether, and M Pranz, and H Wollmann
October 1990, Die Pharmazie,
G Raether, and M Pranz, and H Wollmann
November 1951, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
G Raether, and M Pranz, and H Wollmann
January 1977, Prikladnaia biokhimiia i mikrobiologiia,
G Raether, and M Pranz, and H Wollmann
January 1950, Journal of the American Pharmaceutical Association. American Pharmaceutical Association,
G Raether, and M Pranz, and H Wollmann
January 1959, Pharmaceutica acta Helvetiae,
G Raether, and M Pranz, and H Wollmann
October 1950, The Journal-lancet,
G Raether, and M Pranz, and H Wollmann
February 1958, Il Farmaco; edizione pratica,
G Raether, and M Pranz, and H Wollmann
January 1951, Il Farmaco, scienza e tecnica,
G Raether, and M Pranz, and H Wollmann
January 1968, Acta poloniae pharmaceutica,
Copied contents to your clipboard!